Cancer Research Technology Ltd, the oncology-focused development and commercialisation company owned by charity Cancer Research UK, has established a new crystallography facility based at Birkbeck, University of London.

The agreement provides CRT employees with a base within the college’s School of Crystallography, part of the Birkbeck/UCL Institute of Structural Molecular Biology, at which the team, lead by Andrew Turnbull, will study the structures of drug-protein complexes to aid CRT’s anticancer drug discovery projects, the group said.

Commenting on the move, Tony Raynham, Head of Medicinal Chemistry at CRT, said: “Locating our crystallographers at Birkbeck means we can take advantage of the world-class facilities they have on site. Crystallography is a new asset for us, and one which we very much look forward to making full use of.”

According to CRT, the agreement falls under plans to expand its development laboratories to boost both the number and speed of drug discovery projects in its pipeline, which should see the company’s number of scientific employees swell from around 45 to 90 in the next two years.